Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Assiut University
30 participants
Jan 1, 2022
OBSERVATIONAL
Conditions
Summary
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.
Eligibility
Inclusion Criteria6
- Age from 16 years and older.
- Gender: both sexes are included.
- Clinical Diagnosis of MG with supporting evidence as:
- unequivocal clinical response to pyridostigmine
- decrement \>10% in repetitive nerve stimulations study (RNS).
- Willingness to sample collection, imaging study and other disease-related examinations and assessments.
Exclusion Criteria3
- Age younger than 16 years.
- History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
- Severe systemic illness affecting life-expectancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05214612